Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 3/20 | 0.71 |
| ▸ | NR2C2 | P49116 | 3/20 | 0.71 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.71 |
| ▸ | RELA | Q04206 | 3/20 | 0.71 |
| ▸ | TAB1 | Q15750 | 3/20 | 0.71 |
| ▸ | RAF1 | P04049 | 13/20 | 0.49 |
| ▸ | BRAF | P15056 | 14/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20998564 | 0.88 | NFKB1 (0.75) | NFKB1NR2C2NFKB2RELATAB1 | |
| SCHEMBL18044996 | 0.83 | BTK (0.73) | NFKB1NR2C2NFKB2RELATAB1 | |
| SCHEMBL16670588 | 0.83 | BTK (0.73) | NFKB1NR2C2NFKB2RELATAB1 | |
| SCHEMBL1217377 | 0.74 | RAF1 (0.71) | NFKB1NR2C2NFKB2RELATAB1 | |
| SCHEMBL28427186 | 0.73 | RAF1 (0.63) | NFKB1NR2C2NFKB2RELATAB1 | |
| SCHEMBL1650528 | 0.72 | RAF1 (0.68) | NFKB1NR2C2NFKB2RELATAB1 | |
| SCHEMBL13648120 | 0.72 | RAF1 (0.64) | NFKB1NR2C2NFKB2RELATAB1 | |
| SCHEMBL15573297 | 0.72 | KDR (0.64) | NFKB1NR2C2NFKB2RELATAB1 | |
| SCHEMBL5319531 | 0.72 | KDR (0.67) | NFKB1NR2C2NFKB2RELATAB1 | |
| SCHEMBL16651380 | 0.72 | KDR (0.67) | NFKB1NR2C2NFKB2RELATAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LCK | NFKB1 1405/4885NR2C2 2872/4885NFKB2 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.